1. Home
  2. XYF vs IKT Comparison

XYF vs IKT Comparison

Compare XYF & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo X Financial each representing six

XYF

X Financial each representing six

HOLD

Current Price

$5.16

Market Cap

207.6M

Sector

Finance

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.34

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XYF
IKT
Founded
2014
2008
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.6M
220.5M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
XYF
IKT
Price
$5.16
$2.34
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
69.9K
361.2K
Earning Date
05-18-2026
03-26-2026
Dividend Yield
11.34%
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.30
$1.33
52 Week High
$15.58
$2.61

Technical Indicators

Market Signals
Indicator
XYF
IKT
Relative Strength Index (RSI) 45.83 46.23
Support Level $4.60 $2.29
Resistance Level $5.65 $2.53
Average True Range (ATR) 0.29 0.11
MACD -0.03 -0.02
Stochastic Oscillator 25.79 19.12

Price Performance

Historical Comparison
XYF
IKT

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, guarantee services provided and financing income.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: